Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Nanopore sequencing-based genotyping suggested an association between CYP2D6 function and susceptibility to anxiety and depression.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Biomed Central, 2008.
    • Subject Terms:
      Cytochrome P-450 CYP2D6*/genetics ; Anxiety*/genetics ; Depression*/genetics ; Genetic Predisposition to Disease* ; Nanopore Sequencing*/methods; Humans ; Male ; Female ; Adult ; Middle Aged ; Genotype ; Alleles ; Young Adult
    • Abstract:
      Objective: CYP2D6 activity has been inconsistently associated with anxious and depressive personality traits. The inconsistency may stem from limitations of targeted genotyping, employed in most previous studies, leading to undetected errors in metabolic classification. Using a nanopore sequencing-based method, we comprehensively genotyped CYP2D6 alleles in a small cohort of 96 Malaysians and re-examined the relationship between CYP2D6 activity and susceptibility to anxiety and depression.
      Results: In keeping with prior studies, CYP2D6*10 was found to be the most common defective allele. Nearly half of the (48.5%) participants were classified as intermediate and poor metabolizers. Linear regression analysis suggested that impaired CYP2D6 activity could be a predictor of anxiety and depression, consistent with the putative role of CYP2D6 in the synthesis of serotonin and dopamine, the mood-boosting neurotransmitters. We hope this brief report will prompt larger-scale studies to further elucidate the contribution of CYP2D6 to the genetic underpinnings of mental well-being.
      Competing Interests: Declarations. Ethics approval and consent to participate: The study was approved (UKM PPI.800-1/1/5/JEP-2019-391) by the Research Ethics Committee UKM (Human). Informed consent was obtained from all participants. The study was performed in accordance with the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      (© 2025. The Author(s).)
    • References:
      Br J Clin Pharmacol. 2004 Jun;57(6):785-9. (PMID: 15151524)
      Genet Med. 2017 Jan;19(1):69-76. (PMID: 27388693)
      Clin Pharmacol Ther. 2021 Sep;110(3):563-572. (PMID: 34216021)
      Pharmacogenomics J. 2009 Dec;9(6):380-94. (PMID: 19636337)
      Clin Pharmacol Ther. 2007 Feb;81(2):242-51. (PMID: 17259947)
      Psychiatr Genet. 2003 Jun;13(2):111-3. (PMID: 12782969)
      Clin Transl Sci. 2020 Jan;13(1):116-124. (PMID: 31647186)
      Arch Pharm Res. 2018 Sep;41(9):921-930. (PMID: 30191460)
      J Clin Psychopharmacol. 2006 Aug;26(4):440-2. (PMID: 16855473)
      Pharmacogenomics. 2009 Apr;10(4):541-7. (PMID: 19374513)
      Bioinformatics. 2018 Sep 15;34(18):3094-3100. (PMID: 29750242)
      Sci Rep. 2019 Mar 5;9(1):3527. (PMID: 30837593)
      Mol Psychiatry. 2023 Aug;28(8):3243-3256. (PMID: 35854107)
      Br J Clin Pharmacol. 2007 Jul;64(1):96-9. (PMID: 17324244)
      Genet Test Mol Biomarkers. 2017 Jul;21(7):409-415. (PMID: 28525288)
      Acta Psychiatr Scand. 1993 Jan;87(1):23-8. (PMID: 8424321)
      Pharmacogenetics. 1995 Aug;5(4):215-23. (PMID: 8528268)
      Pharmacogenomics. 2008 Jul;9(7):833-40. (PMID: 18597648)
      Drug Metab Pharmacokinet. 2014;29(5):360-6. (PMID: 24647041)
      Bioinformatics. 2018 Aug 1;34(15):2666-2669. (PMID: 29547981)
      Pharmacogenomics. 2009 Jul;10(7):1111-20. (PMID: 19604084)
      Genet Med. 2019 Feb;21(2):361-372. (PMID: 29875422)
      Nature. 2016 Feb 11;530(7589):228-232. (PMID: 26840485)
      J Clin Pharm Ther. 2019 Aug;44(4):508-524. (PMID: 30980418)
      Front Pharmacol. 2018 Apr 05;9:305. (PMID: 29674966)
      Lancet. 1989 Mar 11;1(8637):555. (PMID: 2564084)
      Int J Environ Res Public Health. 2021 Dec 03;18(23):. (PMID: 34886512)
      Mol Psychiatry. 2020 Oct;25(10):2275-2294. (PMID: 30279457)
    • Grant Information:
      GUP-2018-045 Universiti Kebangsaan Malaysia
    • Contributed Indexing:
      Keywords: Anxiety; CYP2D6; Depression; Nanopore sequencing
    • Accession Number:
      EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
    • Publication Date:
      Date Created: 20250227 Date Completed: 20250228 Latest Revision: 20250302
    • Publication Date:
      20250302
    • Accession Number:
      PMC11869584
    • Accession Number:
      10.1186/s13104-025-07156-9
    • Accession Number:
      40016731